|
MechanismHIV envelope protein gp120 inhibitors [+3] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
A Phase I Single-Blind Randomised Trial Investigating Immunisation Strategies Using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA Combinations in Order to Maximise Antibody Responses to Human Immunodeficiency Virus
This is a randomised two-part Phase I study which will explore the impact of different boosting options (MVA-CN54 and recombinant CN54gp140 protein) for oral Adenovirus serotype 4 vector prime expressing HIV-1 CN54 envelope (Ad4-EnvCN54) designed to optimize systemic and mucosal antibody responses.
Part 1 is exploratory and designed to select conditions capable of promoting enhanced systemic and mucosal B cell responses in a limited number of participants. Part 2 is dependent upon Part 1 and is designed to study groups selected on performance in part 1 in an expanded number of subjects. Data from both stages will be combined for safety and immunological analyses.
100 Clinical Results associated with HIV envelope protein gp120 x HIV-1 nef x HIV gag x HIV-1 pol
100 Translational Medicine associated with HIV envelope protein gp120 x HIV-1 nef x HIV gag x HIV-1 pol
0 Patents (Medical) associated with HIV envelope protein gp120 x HIV-1 nef x HIV gag x HIV-1 pol